

DAFTAR PUSTAKA

- Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. 2013. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. *Journal of Hematology & Oncology*. 6:88.
- Alexiou GA, Sioka C. 2015. Mobile phone use and risk for intracranial tumors. *J Negat Results Biomed*. 23;14:23.
- Amlin-Van Schaick JC, Kim S, DiFabio C, Lee MH, Broman KW, Reilly KM. 2012. Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. *Neuro Oncol*. 14(2):160-74.
- Andisheh-Tadbir A, Mardani M, Pourshahidi S, Nezarati K, Bahadori P. 2016. Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis. *J Clin Exp Dent*. 8(2):e130-5.
- Anonim. 2016. Kapa Sybr Fast One-step qRT-PCR Kit. *Kapa Biosystems*. Massachusetts.
- Antonelli M, Massimino M, Morra I, Garre ML, Gardiman MP, Buttarelli FR, Arcella A, Giangaspero F. 2012. Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance. *Neuropathology*. 32(2):133-8.
- Banerji U, Dean EJ, Perez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Davies B, Elvin P, Lawrence P, Yates JWT, Helen Ambrose H, Rugman P, Foxley A, Salim S, Casson E, P O Lindemann JPO, Schellens JHM. 2015. A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. *J Clin Oncol*.;33(suppl):2500.
- Banks WA. 2015. The blood-brain barrier in neuroimmunology: Tales of separation and assimilation. *Brain Behav Immun*. 44:1-8.
- Benson VS, Pirie K, Schüz J, Reeves GK, Beral V, Green J, Banks E, Beral V, Church J, English R, Green J, Patnick J, Peto R, Reeves G, Vessey M, Wallis M, Abbott S, Armstrong M, Balkwill A, Benson V, Beral V, Black J, Brown A, Bull D, Cairns B, Callaghan K, Canoy D, Chadwick A, Chivenga J, Crossley B, Crowe F, Ewart D, Ewart S, Fletcher L, Floud S, Gathani T, Gerrard L, Goodill A, Green J, Guiver L, Kan SW, Kirichek O, Keene C, Kroll M, Langston N, Lingard I, Lowe P, Luque MJ, Moser K, Pank L,

- Pirie K, Reeves G, Sherman E, Sherry-Starmer E, Schmidt J, Simmonds M, Strange H, Sweetland S, Timadger A, Tipper S, Travis R, Trickett L, Wright L, Yang O. 2013. Mobile phone use and risk of brain neoplasms and other cancers: prospective study. *Int J Epidemiol.* 42(3):792-802.
- Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJ. 2013. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. *Clin Cancer Res.* 19(24):6716-29.
- Bidinotto LT, Torrieri R, Mackay A, Almeida GC, Viana-Pereira M, Cruvinel-Carlioni A, Spina ML, Campanella NC, Pereira de Menezes W, Clara CA, Becker AP, Jones C, Reis RM. 2016. Copy Number Profiling of Brazilian Astrocytomas. *G3 (Bethesda).* 6(7):1867-78.
- Birner P, Pusch S, Christov C, Mihaylova S, Toumangelova-Uzeir K, Natchev S, Schoppmann SF, Tchobanov A, Streubel B, Tuettenberg J, Guentchev M. 2014. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. *Cancer.* 120(16):2440-7.
- Bleeker FE, Molenaar RJ, Leenstra S. 2012. Recent advances in the molecular understanding of glioblastoma. *Journal of Neuro-Oncology* 108 (1): 11–27.
- Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, Bardelli A. 2014. Mutational profiling of kinases in glioblastoma. *BMC Cancer* 14: 718.
- Brat DJ, dan Perry A. 2010. *Practical Neurosurgical Pathology, A Diagnostic Approach.* Elsevier Saunders. Philadelphia
- Bullwinkel J, Baron-Lühr B, Lüdemann A, Wohlenberg C, Gerdes J, Scholzen T. 2006. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. *J. Cell. Physiol.* 206 (3): 624-35.
- Burris H, Siu LL, Infante JR, Wheler JJ, Kurkjian C, Opalinska J, Smith DA, Antal JM, Gauvin JL, Gonzalez T, Adams LM, Bedard P, Gerecitano JF, Kurzrock R, Moore KN, Morris SR, Aghajanian C. 2011 Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study *J Clin Oncol.*;29(suppl):3003.
- Cavenee WK, Furnari FB, Nagane M, Huang HJS, Newcomb EW, Bigner DD, Weller M, Berens ME, Plate KH, Israel MA, Noble MD, Kleihues P. 2000. Diffusely infiltrating astrocytomas dalam *Pathology and genetics of tumours of the nervous system.* WHO classification of tumours. IARC. Lyon. p10-21.

- CBTRUS. 2012. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision). Source: *Central Brain Tumor Registry of the United States*, Hinsdale, Illinois.
- Chen WJ, He DS, Tang RX, Ren FH, Chen G. 2015. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. *Asian Pac J Cancer Prev*. 16(2):411-20.
- Chowdhury I, Thompson WE, Thomas K. 2014. Prohibitins role in cellular survival through Ras-Raf-MEK-ERK pathway. *J Cell Physiol*. 229(8):998-1004.
- Chung E, Kondo M. 2011. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. *Immunol Res*. 49(1-3):248-68.
- Clancy S, Brown W. 2008. Translation, DNA to mRNA to Protein. *Nature Education* 1(1):101.
- Collins VP, Jones DTW, Giannini C. 2015. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. *Acta Neuropathol*. 129(6): 775–788.
- Danysh HE, Mitchell LE, Zhang K, Scheurer ME, Lupo PJ. 2015. Traffic-related air pollution and the incidence of childhood central nervous system tumors: Texas, 2001-2009. *Pediatr Blood Cancer*. 62(9):1572-8.
- Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko ZN, Martelli AM, Cocco L, Steelman LS, McCubrey JA. 2014. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. *Oncotarget*, 5(13): 4603–4650.
- Floc'h N, Abate-Shen C. 2012. The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer. *Oncotarget*. 3(12): 1483–1484.
- Forsyth TM, Bi WL, Abedalthagafi M, Dunn IF, Chiocca EA. 2015. Extracranial growth of glioblastoma multiforme. *J Clin Neurosci*. 22(9):1521-3.
- Gimsa U, Mitchison NA, Brunner-Weinzierl MC. 2013. Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. *Mediators Inflamm*. 2013:320519.

GLOBOCAN 2012, *Cancer Incidence, Mortality and Prevelence Worldwide*. Lyon. Available at www.dep_iarc.fr./globocan/globocan.html

Groblewska M, Siewko M, Mroczko B, Szmitkowski M. 2012. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. *Folia Histochem. Cytobiol.* 50 (1): 12–9.

Gry M, Rimini R, Strömberg S, Asplund A, Pontén F, Uhlén M, Nilsson P. 2009. Correlations between RNA and protein expression profiles in 23 human cell lines. *BMC Genomics.* 10:365.

Guo Y, Xiao P, Lei S, Deng F, Xiao GG, Liu Y, Chen X, Li L, Wu S, Chen Y, Jiang H, Tan L, Xie J, Zhu X, Liang S, Deng H. 2008. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. *Acta Biochim Biophys Sin.* 40(5):426-36.

Hanahan D, Weinberg RA. 2011. Hallmarks of Cancer: The Next Generation. *Cell.* 144, 6:646-74.

Hatem R, El Botty R, Chateau-Joubert S, Servely JL, Labiod D, de Plater L, Assayag F, Coussy F, Callens C, Vacher S, Reyat F, Cosulich S, Diéras V, Bièche I, Marangoni E. 2016. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. *Oncotarget.* (in press)

He F, Xia Y, Liu H, Li J, Wang C. 2013. P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis. *Tumour Biol.* 34(5):3121-30.

Hernandez-Garzón E, Fernandez AM, Perez-Alvarez A, Genis L, Bascuñana P, Fernandez de la Rosa R, Delgado M, Angel Pozo M, Moreno E, McCormick PJ, Santi A, Trueba-Saiz A, Garcia-Caceres C, Tschöp MH, Araque A, Martin ED, Torres Aleman I. 2016. The insulin-like growth factor I receptor regulates glucose transport by astrocytes. *Glia.* Jul 27. (in press.)

Ho AL, Koch MJ, Tanaka S, Eichler AF, Batchelor TT, Tanboon J, Louis DN, Cahill DP, Chi AS, Curry WT Jr. 2016. Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. *J Clin Neurosci.* pii: S0967-5868(16)00123-5.

Hu J, Markowitz G, Wang XF. 2016. Isolation of Glioma-Initiating Cells for Biological Study. *Adv Exp Med Biol.* 899:197-209.

Hubbard SR, Miller WT. 2007. Receptor tyrosine kinases: mechanisms of activation and signaling. *Curr Opin Cell Biol.* 19(2): 117-23.

- Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. 2007. Estimating Sample Size and Power: Applications and Examples, dalam Designing Clinical Research. Wolters Kluwer, Lippincott Williams Wilkins. p89.
- Japardi I. 2003. *Astrositoma* : insidens dan pengobatannya. *J Kedokter Trisakti*. 22(3):110-5.
- Jenkinson MD; Smith TS; Haylock B; Husband D; Shenoy A; Vinjamuri S; Walker C; Pietronigro D; Warnke PC. 2010. "Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma". *Journal of Neuro-Oncology*.; 99 (1): 103-13.
- Jin TB, Zhang JY, Li G, Du SL, Geng TT, Gao J, Liu QP, Gao GD, Kang LL, Chen C, Li SQ. 2013. RTEL1 and TERT polymorphisms are associated with astrocytoma risk in the Chinese Han population. *Tumour Biol*. 34(6):3659-66.
- Johannessen A, Torp S: 2006. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. *Pathol Oncol Res*, 12:143-147.
- Josephs DH, Sarker D. 2015. Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics. *Transl Oncogenomics*.; 7(Suppl 1): 33–49.
- Jung BK, Song H, Kim MJ, Cho J, Shin EH, Chai JY. 2016. High Toxoplasma gondii Seropositivity among Brain Tumor Patients in Korea. *Korean J Parasitol*.54(2):201-4.
- Jurič DM, Kržan M, Lipnik-Stangelj M. 2016. Histamine and astrocyte function. *Pharmacol Res*. 111:774-783.
- Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK. 2010. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. *Mol Cancer Ther*. 9(5):1298-307.
- King D, Yeomanson D, Bryant HE. 2015. PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma. *Journal of Pediatric Hematology/Oncology*. 37 (4): 245–51.
- Kleihues P, Louis DN, Wiestler OD, Burger PC, B.W. Scheithauer BW. 2007. WHO grading of tumours of the central nervous system, dalam *WHO Classification of Tumours of the Central Nervous System*. IARC, Lyon.
- Komiya Y, Habas R. 2008. Wnt signal transduction pathways. *Organogenesis*. 4(2):68-75.

- Kunkle BW, Sandberg D, Jayakar P, Felty Q, Roy D. 2010. Gene-Environment Interaction and Susceptibility to Pediatric Brain Tumors dalam *Environmental Factors, Genes, and the Development of Human Cancers*. Springer. New York. p.223-252.
- Kunkle BW, Bae S, Singh KP, Roy D. 2014. Increased risk of childhood brain tumors among children whose parents had farm-related pesticide exposures during pregnancy. *JP J Biostat*. 11(2):89-101.
- Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. *Cell*. 141(7):1117-34.
- Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM. 2004. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. *Breast Cancer Res Treat*. 88(1):75-85.
- Li L, Yin J, Li Y, Tian W, Qiao B, Tang Z, Shi J. 2013. Anaplastic astrocytoma masquerading as hemorrhagic stroke. *J Clin Neurosci*. 20(11):1612-4.
- Liang Q, Ma C, Zhao Y, Gao G, Ma J. 2013. Inhibition of STAT3 Reduces Astrocytoma Cell Invasion and Constitutive Activation of STAT3 Predicts Poor Prognosis in Human Astrocytoma. *PLoS One*. 8(12): e84723.
- Liu B, Cui J, Sun J, Li J, Han X, Guo J, Yi M, Amizuka N, Xu X, Li M. 2016. Immunolocalization of MMP9 and MMP2 in osteolytic metastasis originating from MDA-MB-231 human breast cancer cells. *Mol Med Rep*. 14(2):1099-106.
- Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee WK, Ren B, Mischel PS. 2015. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. *Mol Cell*. 60(2):307-18.
- Liu L, Li W, Xia H, Zhu Z, Luan X. 2014. Differential expression and clinical significance of glioblastoma mRNA expression profiles in Uyghur and Han patients in Xinjiang province. *Med Sci Monit*. 20:2404-13.
- Liu W, Zhou Y, Reske SN, Shen C. 2008. PTEN mutation: many birds with one stone in tumorigenesis. *Anticancer Res*. 28(6A):3613-9.
- Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. 2000. The Life Cycle of Cells, dalam *Molecular Cell Biology*. 4th edition. W. H. Freeman. New York.

- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. 2007. WHO Classification of Tumours of the Central Nervous System. IARC, Lyon.
- Lui VWY, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert B, Freilino M, Sauerwein S, Peyser N, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Ng PKS, Garraway LA, Hammerman PS, Mills GB, Grandis JR. 2013. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. *Cancer Discov.* 3(7): 761–769.
- Maiese K, Zhao ZC, Yan CS, Shaohui W. 2013. mTOR: On Target for Novel Therapeutic Strategies in The Nervous System. *Trends in Molecular Medicine* 19(1): 51-60.
- McCubrey JA, Steelman LC, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim Biophys Acta.* 1773(8):1263-84.
- Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaity F, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH. 2014. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. *Anticancer Res.* 34(3):1355-66.
- MingHao W, Qianze D, Di Z, YunJie W. 2011. Expression of delta-catenin is associated with progression of human astrocytoma. *BMC Cancer.* 11: 514.
- Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW. 2008. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. *J Clin Oncol.* 26(3):361–7.
- Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiet M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl JB, Westphal M, Pantel K, Riethdorf S. 2014. Hematogenous dissemination of glioblastoma multiforme. *Sci Transl Med.* 30;6(247):247
- Nagase H, Visse R, Murphy G. 2006. Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc Res.* 69(3):562-73.

- Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. 2013. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. *Mod Pathol*. 26(4):465-84.
- Ohtaki S, Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Noshiro S, Akiyama Y, Mikami T, Mikuni N, Kocsis JD, Honmou O. 2016. ACTC1 as an invasion and prognosis marker in glioma. *J Neurosurg*. 15:1-9.
- Pećina-Šlaus N, Kafka A, Varošanec AM, Marković L, Krsnik Ž, Njirić N, Mrak G. 2016. Expression patterns of Wnt signaling component, secreted frizzled-related protein 3 in astrocytoma and glioblastoma. *Mol Med Rep*. 13(5):4245-51.
- Pekny M, Pekna M. 2016. Reactive gliosis in the pathogenesis of CNS diseases. *Biochim Biophys Acta*. 1862(3):483-91.
- Pietruszewska W, Bojanowska-Poźniak K, Kobos J. 2016. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study. *Otolaryngol Pol*. 70(3):32-43.
- Rafalski VA, Brunet A. 2011. Energy metabolism in adult neural stem cell fate. *Progress in Neurobiology*, 93 (2): 182–203.
- Rahmanzadeh R, Hüttmann G, Gerdes J, Scholzen T. 2007. Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. *Cell Prolif*. 40 (3): 422-30.
- Rejto PA, Abraham RT. 2014. MTOR mutations in the crosshairs of targeted therapy. *Cancer Discov*. 4(5):513-5.
- Rivera RA, Castillo-Pichardo L, Gerena Y, Dharmawardhane S. 2016. Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade. *Plos One*. 10;11(6):e0157251.
- Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD. 2011. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. *Genome Res*. 21(1):47-55.
- Rosenblum M K. 2011. Central nervous system, dalam: Rosai, Juan. *Rosai and Ackerman's Surgical Pathology*. 10th ed. Mosby Elsevier. Missouri.

- Scheithauer BW, Hawkins C, Tihan T, Vanden Berg SR, Burger PC. 2007. Pilocytic astrocytoma, dalam *WHO Classification of Tumours of the Central Nervous System*. IARC, Lyon.
- Schmidt MH, Broll R, Bruch HP, Finniss S, Bogler O, Duchrow M. 2004. Proliferation marker pKi-67 occurs in different isoforms with various cellular effects. *J Cell Biochem*. 91(6):1280-1292
- Shannon JB. 2010. Brain disorders Sourcebook 3E, Omnigraphics. Detroit. 140-1.
- Sica RE, Caccuri R, Quarracino C, Capani F. 2016. Are astrocytes executive cells within the central nervous system? *Arq Neuropsiquiatr*. 74(8):671-8.
- Slomovitz BM, Coleman RL. 2012. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. *Clin Cancer Res*. 18:5856-5864.
- TCGAT Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*.; 455:1061–1068.
- Tran LM, Chang CJ, Plaisier S, Wu S, Dang J, Mischel PS, Liao JC, Graeber TG, Wu H. 2012. Determining PTEN Functional Status by Network Component Deduced Transcription Factor Activities. *PLoS One*. 7(2): e31053.
- Tserga A, Chatziandreou I, Michalopoulos NV, Patsouris E, Saetta AA. 2016. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. *Virchows Arch*. 469(1):35-43.
- Tutt B. 2011. Glioblastoma cure remains elusive despite treatment advances. *Oncolog*. 56(3):1.
- Ung MH, Wang GL, Varn FS, Cheng C. 2016. Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis. *Oncotarget*. 11776.
- van Vandooren J, den Steen PE, Opdenakker G. 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) The next decade. *Crit Rev Biochem Mol Biol*. 48 (3): 222–72.
- Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P; EUROCORE-5 Working Group. 2015. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCORE-5 study. *Eur J Cancer*. pii: S0959-8049(15)00712-1.

- von Deimling A, Burger PC, Nakazato Y, Ohgaki H, Kleihues P. 2007. Diffuse astrocytoma dalam *WHO Classification of Tumours of the Central Nervous System*. IARC, Lyon.
- Wang L, Xu J, Zhao C, Zhao L, Feng B. 2013. Antiproliferative, cell-cycle dysregulation effects of novel asiatic acid derivatives on human non-small cell lung cancer cells. *Chem Pharm Bull (Tokyo)*. 61(10):1015-23.
- Wegman-Ostrosky T, Reynoso-Noverón N, Mejía-Pérez SI, Sánchez-Correa TE, Alvarez-Gómez RM, Vidal-Millán S, Cacho-Díaz B, Sánchez-Corona J, Herrera-Montalvo LA, Corona-Vázquez T. 2016. Clinical prognostic factors in adults with astrocytoma: Historic cohort. *Clin Neurol Neurosurg*. 146:116-22.
- Westin JR. 2014. Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma. *Clin Lymphoma Myeloma Leuk*, 14(5):335-42.
- Wiame I, Remy S, Swennen R, Sági L. 2000. Irreversible heat inactivation of DNase I without RNA degradation. *Biotechniques*. 29(2):252-4, 256.
- Wu HC, Huang KH, Peng KY, Tsai YC, Wu CH, Wang SM, Yang SY, Lin LY, Chang CC, Lin YH, Lin SL, Chu TS, Wu KD. 2015. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. *Sci Rep*. 12;5:11396.
- Xiao B, Chen D, Luo S, Hao W, Jing F, Liu T, Wang S, Geng Y, Li L, Xu W, Zhang Y, Liao X, Zuo D, Wu Y, Li M, Ma Q. 2016. Extracellular translationally controlled tumor protein promotes colorectal cancer invasion and metastasis through Cdc42/JNK/ MMP9 signaling. *Oncotarget*. (in press)
- Xie H, Li L, Zhu G, Dang Q, Ma Z, He D, Chang L, Song W, Chang HC, Krolewski JJ, Nastiuk KL, Yeh S, Chawnshang Chang C. 2015. Infiltrated pre-adipocytes increase prostate cancer metastasis *via* modulation of the miR-301a/androgen receptor (AR)/TGF- β 1/Smad/MMP9 signals. *Oncotarget*. 6(14): 12326–12339.
- Xue G, Romano E, Massi D, Mandalà M. 2016. Wnt/ β -catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. *Cancer Treat Rev*. 49:1-12.
- Yan Y, Wagle M-C, Punnoose EA, Musib L, Budha N, Nannini M. 2011. A first-in-human trial of GDC-0068: a novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues, *AACR- NCI- EORTC International Conference: Molecular Targets and Cancer Therapeutics*. San Francisco, California: p. B154.

- Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. 2011. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. *J Clin Oncol.* 29(35):4688-95.
- Yu Y, Luk F, Yang JL, Walsh WR. 2011. Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model. *Anticancer Res.* 31(4):1147-52.
- Zahonero C, Sepúlveda JM, Sánchez-Gómez P. 2015. Epidermic growth factor receptor (EGFR) in glioblastomas: the mechanism of tumorigenesis and its role as a therapeutic target. *Rev Neurol.* 61(2):85-93.
- Zhu W, Shao Y, Yang M, Jia M, Peng Y. 2016. Asparaginyl endopeptidase promotes proliferation and invasiveness of prostate cancer cells via PI3K/AKT signaling pathway. *Gene.* pii: S0378-1119(16)30695-3.